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INTRODUCTION
Cutaneous melanoma presents significant
morbidity and mortality. Its incidence has been
increasing all over the world over the last 50
years. Nowadays, about 90% of them are diag-
nosed by clinical examination and most of them
are localized melanomas.1 Thus, more atten-
tion has been paid to this kind of patient.
Sentinel node biopsy has brought about
a new and interesting approach towards lo-
calized cutaneous melanoma.2 The sentinel
node represents the pathological status of
the lymphatic basin. Currently, it is known
that the sentinel node status is the most im-
portant prognostic factor for localized cu-
taneous melanoma.3 The detection of
micrometastases at sentinel nodes improves
the accuracy of staging, and provides valu-
able prognostic information for guiding
subsequent treatment.4-7
In the beginning, sentinel node evalua-
tions was done via hematoxylin and eosin on
serial sections. Later on, immunohistochemi-
cal studies (HMB-45 and S-100 protein)
were added, improving the diagnosis of
micrometastases.8 Recently, methods based
on the reverse transcriptase-polymerase chain
reaction have been used for diagnosing
micrometastases.9,10
It is believed that micrometastases de-
tected by the reverse transcriptase-polymerase
chain reaction are really metastases with bio-
logical significance.11-13 However, the relevance
of micrometastases detected by the reverse
transcriptase-polymerase chain reaction in re-
lation to melanoma recurrence is not well es-
tablished yet. To address this interesting ques-
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CONTEXT: Cutaneous melanoma presents significant
morbidity and mortality. Nowadays, about 90%
of them are diagnosed by clinical examination and
most are localized melanomas. Sentinel node bi-
opsy has brought about a new and interesting ap-
proach towards localized cutaneous melanoma.
The meaning of micrometastases in sentinel nodes
diagnosed by the reverse transcriptase-polymerase
chain reaction is not well established.
OBJECTIVE: To define the real value of micrometastases
diagnosed by the reverse transcriptase-polymerase
chain reaction in relation to melanoma recurrence.
METHODS: Systematic literature review and meta-analy-
sis. The Cochrane Library, Medline, Embase and
Lilacs were the databases searched. We used the
following key words: sentinel node and melanoma;
sentinel node and reverse transcriptase-polymer-
ase chain reaction; melanoma and reverse tran-
scriptase-polymerase chain reaction. Cohort stud-
ies enrolling localized cutaneous melanoma pa-
tients who underwent sentinel node biopsy were
selected. Sentinel node evaluations included
hematoxylin and eosin, immunohistochemistry and
reverse transcriptase-polymerase chain reaction.
RESULTS: Out of the 1,542 studies evaluated, four were
eligible. The four studies, when combined, were
statistically homogeneous. The sample totaled 450
patients grouped as follows: 163 with a sentinel
node negative to hematoxylin eosin and immuno-
histochemistry and positive to the reverse tran-
scriptase-polymerase chain reaction; 192 with a
sentinel node negative to hematoxylin eosin, im-
munohistochemistry and the reverse transcriptase-
polymerase chain reaction and 95 patients with a
sentinel node positive to hematoxylin eosin and/
or immunohistochemistry. We analyzed the first two
groups. The meta-analysis for the random model
showed an increased effect from a positive reverse
transcriptase-polymerase chain reaction on the re-
currence rate. A similar result occurred in the meta-
analysis for the fixed effect model.
CONCLUSION: Patients with a positive reverse tran-
scriptase-polymerase chain reaction had a greater
recurrence rate than those with a negative reverse
transcriptase-polymerase chain reaction. This sug-
gests an important role for the reverse transcriptase-
polymerase chain reaction in sentinel node exami-
nations. In view of the small sample, a clinical trial
could better evaluate this question.
KEY WORDS: Reverse transcriptase. Polymerase chain
reaction. Sentinel node. Melanoma. Microme-
tastasis. Immunohistochemistry.
tion, we systematically reviewed the literature
and performed a meta-analysis.
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METHODS
We used the following key words for our
systematic literature review: melanoma and sen-
tinel node; melanoma and reverse transcriptase-
polymerase chain reaction; and sentinel node
and reverse transcriptase-polymerase chain re-
action. The Cochrane Library, Medline,
Embase and Lilacs were the databases used. We
hand-searched all the bibliographies of the re-
ports, papers and textbooks that we reviewed,
without limiting dates or languages.
We selected cohort studies that evaluated
patients with localized cutaneous melanoma
who underwent sentinel node biopsy. Stud-
ies were initially selected by the title and ab-
stract information, and then submitted to
two reviewers. Sentinel node biopsies were
performed using preoperative lymphoscin-
tigraphy, intraoperative gamma probe detec-
tion and/or lymphatic mapping. The inclu-
sion criteria can be seen in Table 1. Two
groups were compared: a) patients with a sen-
tinel node negative to hematoxylin and eosin,
immunohistochemistry and reverse tran-
scriptase-polymerase chain reaction; b) pa-
tients with a sentinel node negative to
hematoxylin and eosin and immunohisto-
chemistry, but positive to the reverse tran-
scriptase-polymerase chain reaction. The
main variable focused on was melanoma re-
currence. The relative risk was calculated us-
ing the Review Manager (RevMan) software,
considering not only random effects14 but
also fixed effect models.15-18
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RESULTS
The studies selected for the systematic lit-
erature review are described in Table 2. The elec-
tronic search identified 1,542 references in all
databases. Fifteen studies met the inclusion cri-
teria. Eleven studies were excluded because the
follow-up was less than 12 months or there was
insufficient data on the recurrence rate. Thus,
four studies were eligible.19-22 When the four
studies were pooled, it could be demonstrated
that there was statistical homogeneity in terms
of the effect (X2 = 3.17, p = 0.37) (confidence
interval = 95%). The sample size of the four
Table 2. Final selection from the systematic literature review
Study Patients HE and/or IHC positive HE and IHC negative HE and IHC negative
RT-PCR positive RT-PCR negative
Recurrence/Total Recurrence/Total Recurrence/Total
Joseph et al.19, 1997 29 5/11 2/8 1/10
Bostick et al.20, 1999 72 5/17 3/20 0/35
Blaheta et al.21, 2000 116 9/15 4/21 10/80
Li et al.22, 2000 233 18/52 11/114 1/67
Total 450 37/95 20/163 12/192
HE: Hematoxylin and eosin; IHC: Immunohistochemistry; RT-PCR: Reverse transcriptase polymerase chain reaction.
Table 1. Inclusion criteria used for the systematic review
CRITERIA DESCRIPTION
Study design Cohort (prognostic study)
Sample No limit
Objective To access the recurrence rate of cutaneous melanoma among patients undergoing sentinel node biopsy
Patients Presented localized cutaneous melanoma undergoing sentinel node biopsy
Interventions made Preoperative lymphoscintigraphy, Intraoperative lymphatic mapping, Intraoperative gamma detection,
Sentinel node biopsy, Sentinel node examination, hematoxylin and eosin, immunohistochemistry and
reverse transcriptase polymerase chain reaction
Duration of follow-up (mean or median) More than 12 months
Lost to follow-up Less than 10%
Statistical methods Descriptive statistics with total number and percentage of recurrence
included studies totaled 450 patients. These
patients were grouped as follows: 163 had nega-
tive hematoxylin and eosin, negative immuno-
histochemistry and a positive reverse tran-
scriptase-polymerase chain reaction; 192 had
negative hematoxylin and eosin, negative im-
munohistochemistry and a negative reverse
transcriptase-polymerase chain reaction and 95
patients had a positive sentinel node upon
pathological examination (hematoxylin and
eosin and/or immunohistochemistry). Only the
first two groups were objects of our analysis.
The meta-analyses for random model ef-
fect showed an increased recurrence rate caused
by a positive reverse transcriptase-polymerase
chain reaction (relative risk = 2.55 [1.06, 6.12])
(Figure 1). The same was observed in meta-
analyses using fixed model effect (relative risk
= 3.16 [1.39, 7.19]) (Figure 2).
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DISCUSSION
Sentinel node biopsy allows for more ac-
curate prognostic information for patients with
localized cutaneous melanoma. The sentinel
node status identifies homogeneous patient
populations for clinical trials and selects patients
for lymph node dissection decisions and/or
Figure 1. Melanoma recurrence risk due to micrometastasis diagnosed by reverse transcriptase polymerase chain reaction. Meta-analysis using random model (RR).
Test for heterogeneity: chi-squared = 3.17; degrees of freedom = 3; p = 0.37; Teste for overall effect: z = 2.09; p = 0.04.
HE: Hematoxylin and eosin; IHC: Immunohistochemistry; RT-PCR: Reverse transcriptase polymerase chain reaction; CI: Confidence interval.
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adjuvant therapy (interferon alpha-2b).
Optimizing the diagnosis of the microme-
tastasis is just as important as picking out the
correct sentinel node (using an appropriate
technique). Molecular techniques such as the
polymerase chain reaction may be more sensi-
tive than immunohistology, which is more sen-
sitive than histology (hematoxylin and eosin),
and the latter is more sensitive than clinical in-
spection.23,24 The fact that sentinel node
positivity is the strongest prognostic factor for
recurrence of localized cutaneous melanoma
gives importance to micrometastases. Never-
theless, the real value of micrometastases diag-
nosed by the reverse transcriptase-polymerase
chain reaction in relation to melanoma recur-
rence remains an unresolved question. That is
why we conducted this systematic revision.
Molecular diagnosis of micrometastases by
the reverse transcriptase-polymerase chain re-
action has two advantages, at least when com-
pared with immunohistochemistry. First, it has
more sensitivity. Second, it is cheaper and
quicker.25 Some authors question the speci-
ficity of the reverse transcriptase-polymerase
chain reaction, emphasizing the risk of false
positives caused by nevi cells, for example. This
problem can be minimized using more than
one mRNA (messenger ribonucleic acid) ex-
amination, like mRNA-Tyrosinase, mRNA-
MART-1 (melanoma antigen recognized by
T cells-1) and mRNA-MAGE III (melanoma
antigen gene family 3).  A multi-institutional
study – the “Sunbelt Melanoma Trial” – has
addressed issues regarding the relative clinical
significance of microscopic nodal disease de-
termined by histology, immunohisto-
pathology and reverse transcriptase-polymer-
ase chain reaction analysis, using four molecu-
lar markers, MAGE III, MART-1, GP 100
(glycoprotein 100) and Tyrosinase.26
In our study, there was recurrence in
twelve out of the 192 reverse transcriptase-
polymerase chain reaction-negative patients.
Ten of them were in one single study, which
had a higher percentage of patients (65%) with
a Breslow thickness of more than 1.5 mm, and
therefore at higher risk of nodal metastasis.
The combined studies were statistically ho-
mogenous and meta-analysis showed that
melanoma recurrence was significantly influenced
by the presence of micrometastases diagnosed by
reverse transcriptase-polymerase chain reaction
alone. Thus, the detection of micrometastases by
the reverse transcriptase-polymerase chain reac-
tion added prognostic significance to the histopa-
thology examination. This result occurred not only
when a random effect model was used but also
with fixed effect models.
One limitation of this study is a possible
bias in the meta-analysis due the small number
of patients included in the eligible studies (450
patients). However, the concordance of the re-
sults from different analyses minimizes such
limitation.
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CONCLUSION
According to our data, patients with a posi-
tive reverse transcriptase-polymerase chain reac-
tion have more recurrence than those with a
negative reverse transcriptase-polymerase chain
reaction, considering all the patients with nega-
tive histology and immunopathology evalua-
tions. This suggests an important role for the
reverse transcriptase-polymerase chain reaction
in sentinel node examinations. In view of the
small sample, a clinical trial could better evalu-
ate and address this question. It is suggested that
minute tumor deposits from micrometastases in
sentinel nodes have prognostic significance.
Figure 2. Melanoma recurrence risk due to micrometastasis diagnosed by reverse transcriptase polymerase chain reaction. Meta-analysis using fixed model (RR).
Test for heterogeneity: chi-squared = 3.17; degrees of freedom= 3;  p = 0.37
Test for overall effect: z = 2.75;  p = 0.006
HE: Hematoxylin and eosin; IHC: Immunohistochemistry; RT-PCR: Reverse transcriptase- polymerase chain reaction; CI - Confidence interval
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CONTEXTO: O melanoma cutâneo apresenta
importante morbidade e mortalidade. A in-
cidência de melanoma cutâneo vem aumen-
tando em todo o mundo nos últimos 50 anos.
Atualmente, cerca de 90% dos casos são di-
agnosticados pelo exame clínico e, na maio-
ria das vezes, ainda na forma de melanoma
localizado. A biópsia de linfonodo sentinela
trouxe uma nova e interessante abordagem
para o melanoma cutâneo localizado.
OBJETIVO: Definir o real valor de micrometástases
diagnosticadas em linfonodo sentinela através
da técnica de transcriptase reversa associada à
reação de polimerização em cadeia (reverse
transcriptase-polymerase chain reaction, PCR)
na recorrência do melanoma cutâneo.
MÉTODOS: Realizamos uma revisão sistemáti-
ca da literatura com metanálise. Cochrane
Library, Medline, Embase e Lilacs foram os
bancos de dados pesquisados. Foram usadas
as seguintes palavras-chave: sentinel node and
melanoma, sentinel node and reverse
transcriptase-polymerase chain reaction,
melanoma and reverse transcriptase-polymerase
chain reaction. Fez-se seleção de estudos prog-
nósticos coorte, abrangendo pacientes porta-
dores de melanoma cutâneo submetidos a
biópsia de linfonodo sentinela. O exame do
linfonodo sentinela incluiu análise histopa-
tológica por hematoxilina e eosina, imuno-
histoquímica e reação de polimerase em ca-
deia. Foi realizada metanálise através do
software RevMan (Review Manager 4.1-c;
Cochrane Collaboration) com avaliação de
odds ratio e risco relativo, utilizando modelo
de efeito fixo e randômico.
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RESULTADOS: Entre 1.542 estudos identificados,
quatro foram elegíveis para a revisão sistemáti-
ca. Os quatro estudos combinados foram esta-
tisticamente homogêneos (c2 = 2,66, p = 0,44
para odds ratio e c2 = 3,17, p = 0,37 para risco
relativo). A casuística totalizou 450 pacientes.
Esses pacientes foram distribuídos em três gru-
pos: 163 com linfonodo sentinela negativo para
hematoxilina-eosina e imunohistoquímica, sen-
do a reação de polimerase em cadeia positiva;
192 com linfonodo sentinela negativo para
hematoxilina-eosina, imunohistoquímica e a re-
ação de polimerase em cadeia e 95 com
linfonodo sentinela positivo para hematoxilina-
eosina e ou imunohistoquímica. Apenas os dois
primeiros grupos foram objetos de nossa análi-
se. A metanálise utilizando modelo de efeito
randômico mostrou aumento de recorrência
para o grupo com a reação de polimerase em
cadeia positiva (odds ratio = 3,0 [1.16, 7.78] e
risco relativo = 2.55 [1.06, 6.12]). Resultado
similar foi encontrado na metanálise utilizando
modelo de efeito fixo (odds ratio = 3,64 [1.51,
8.76] e risco relativo = 3.16 [1.39, 7.19]).
CONCLUSÃO: Pacientes com reação de
polimerase em cadeia positiva tiveram uma
taxa de recorrência maior que aqueles com re-
ação de polimerase em cadeia negativa. Esse
resultado sugere um importante papel da rea-
ção de polimerase em cadeia no exame do
linfonodo sentinela. Considerando-se a peque-
na casuística, um estudo clínico prospectivo
poderia avaliar melhor esta questão.
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